Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 777 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram-positive Bacterial Infections Clear all
Terminated Phase 3 Interventional Results available

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

NCT04802837
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00423657
View directory record Official record
Conditions
Bacterial Infections
Interventions
ceftaroline, vancomycin plus aztreonam, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
17
States / cities
Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 3, 2026, 10:59 AM EDT
Not listed Not applicable Interventional

Vitamin D Supplementation and TB

NCT01992263
View directory record Official record
Conditions
Tuberculosis, Vitamin D, Immunity
Interventions
Vitamin D (600 IU), Vitamin D (2000 IU), Vitamin D (4000 IU), Placebo
Dietary Supplement · Other
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

NCT01592214
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Placebo, XF-73 in 2% Klucel gel, XF-73 in 4% Klucel gel
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Anaheim, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Pneumonia Vaccine Education Intervention Study

NCT06136832
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccine
Interventions
Pneumococcal Vaccine Education
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 64 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

NCT01643941
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, SA4Ag vaccine high dose, SA3Ag vaccine, Blood sample, Placebo, Colonization swab samples
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Leprosy Skin Test Antigens Trial

NCT00128193
View directory record Official record
Conditions
Leprosy
Interventions
Tuberculin, Purified Protein Derivative, MLSA-LAM, MLCwA, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA

NCT00532324
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
CA-MRSA Decolonization
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Female only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 3, 2026, 10:59 AM EDT
Completed No phase listed Observational

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

NCT00368446
View directory record Official record
Conditions
Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

NCT01932242
View directory record Official record
Conditions
Inhalational Anthrax
Interventions
ETI-204, Placebo
Biological · Other
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Overland Park, Kansas • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

NCT00835237
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
Interventions
Boostrix®, Decavac™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
1,332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • DeLand, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Trial of High-Dose Rifampin in Patients With TB

NCT01408914
View directory record Official record
Conditions
Tuberculosis
Interventions
Higher-Dose Rifampin
Drug
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

NCT01738477
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 30 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
20
States / cities
Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

NCT03891901
View directory record Official record
Conditions
Tuberculosis
Interventions
Imatinib, Isoniazid, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 3, 2026, 10:59 AM EDT
Completed No phase listed Observational

Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults

NCT05283967
View directory record Official record
Conditions
Tuberculosis
Interventions
urine colorimetric assay
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
4 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Newark, New Jersey • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine

NCT02239172
View directory record Official record
Conditions
Anthrax
Interventions
PA83-FhCMB
Biological
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 3, 2026, 10:59 AM EDT
Terminated No phase listed Observational

Small Bowel Transit Time in Clostridium Difficile Colitis

NCT01309750
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Small Bowel Transit Study
Radiation
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 3, 2026, 10:59 AM EDT
Recruiting Not applicable Interventional

Cigarette Filter Study

NCT07348679
View directory record Official record
Conditions
Smoking ( Cigarette)
Interventions
Charcoal filtered cigarettes with marketing, Charcoal filtered cigarette without marketing, Non-charcoal filtered cigarettes
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Study of XOMA 3AB

NCT01357213
View directory record Official record
Conditions
Botulism
Interventions
XOMA 3AB, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 3, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional

Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease

NCT00130260
View directory record Official record
Conditions
Staphylococcal Infections, Chronic Kidney Failure
Interventions
Staph aureus types 5 and 8 conjugate vaccine, placebo
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

NCT00096850
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Atazanavir, Rifampin, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
3
States / cities
Palo Alto, California • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

NCT05831124
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Hialeah, Florida • Hollywood, Florida • Columbia, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 3, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

NCT01048697
View directory record Official record
Conditions
Obesity, Tuberculosis
Interventions
Ethambutol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 3, 2026, 10:59 AM EDT